Apontis Pharma AG
XETRA:APPH
Apontis Pharma AG
Total Equity
Apontis Pharma AG
Total Equity Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Equity | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Apontis Pharma AG
XETRA:APPH
|
Total Equity
€30.3m
|
CAGR 3-Years
106%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ATAI Life Sciences NV
NASDAQ:ATAI
|
Total Equity
$243m
|
CAGR 3-Years
39%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bayer AG
XETRA:BAYN
|
Total Equity
€31.9B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
5%
|
|
|
Merck KGaA
XETRA:MRK
|
Total Equity
€29.9B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
|
Dermapharm Holding SE
XETRA:DMP
|
Total Equity
€583.7m
|
CAGR 3-Years
11%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
PharmaSGP Holding SE
XETRA:PSG
|
Total Equity
€39.8m
|
CAGR 3-Years
51%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Apontis Pharma AG
Glance View
APONTIS PHARMA AG engages in the development, promotion, and sale of single pills and other pharmaceutical products. The company is headquartered in Monheim Am Rhein, Nordrhein-Westfalen and currently employs 176 full-time employees. The company went IPO on 2021-05-11. The firm focuses on the commercialization of pharmaceutical products to General Practitioners and engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany.
See Also
What is Apontis Pharma AG's Total Equity?
Total Equity
30.3m
EUR
Based on the financial report for Dec 31, 2023, Apontis Pharma AG's Total Equity amounts to 30.3m EUR.
What is Apontis Pharma AG's Total Equity growth rate?
Total Equity CAGR 3Y
106%
Over the last year, the Total Equity growth was -27%. The average annual Total Equity growth rates for Apontis Pharma AG have been 106% over the past three years .
You don't have any saved screeners yet